Module 3: Vaccine Development
Vaccine Discovery
18 October, 2007 Thursday
0900-0930 Historical of vaccine Discovery
Dr. Howard Engers, AHARI, Ethiopia
0930-1030 Overview of modern vaccine discovery
Dr.
Howard Engers,
AHARI, Ethiopia
1030-1100 Tea break
1100-1200 Screening for antigens
Prof. Dr. Kenji Hirayama,
1200-1330 Lunch
1330-1430 Evaluating antigens
Prof.
Dr. Kenji Hirayama,
1430-1500 Tea break
1500-1600 Visiting Vaccine
Discovery Laboratory Institute
of Tropical Medicine,
19
October, 2007
Friday
0900-1030 Adjuvant -
Dr. Howard Engers,
AHARI, Ethiopia
1030-1100 Tea
break
1100-1200 Alternatives to antigens: DNA vaccine, Live or attenuated pathogen
Dr. Howard Engers, AHARI,
Ethiopia
1200-1330 Lunch
1330-1430 Selection
of development candidate and back-ups
Dr. Howard Engers, AHARI, Ethiopia
1430-1500 Tea break
1500-1630
Efficacy,
toxicity, route if immunization, price, stability, cold chain,
Dr. Howard Engers, AHARI, Ethiopia
20 October, 2007 Saturday
0900-1030 Malaria vaccine discovery
1030-1100 Tea
break
1100-1200 Cholera vaccine
discovery
1200-1300 Lunch
1300-1400 Oral
vaccine discovery
Dr. Takeshi Arakawa,
Antigen Development
22 October, 2007 Monday
0900-1200 Antigen
Development:
·
History of Vaccine Development
·
Down period-Try and error
period
·
The 2nd period - Toxoid
vaccine
·
The 3rd period - Virus
vaccines period
·
The 4th period - Genetic
engineering period
Dr.
Process of Vaccine Production
Dr.
Process of Vaccine Production (Continued)
Dr.
1200-1300
Lunch
1300-1415 Quality Assurance of Vaccine
Dr. Nobuhiro Noro, Glaxo SmithKlein KK, Tokyo, Japan
1415-1430 Tea break
1430-1600 Quality Assurance of Vaccine (Continued)
Dr. Nobuhiro
Noro, Glaxo SmithKlein KK, Tokyo, Japan
Pre-Clinical Development
23 October, 2007
Tuesday
0900-1030 Safety
assessment
Toxicity test for animal: regional complications,
systemic toxicity such
as fever, anaphylactic shock
Dr. Nobuhiro Noro, Glaxo SmithKlein KK, Tokyo, Japan
1030-1100 Tea break
1100-1230 Immunogenicity assessment
Dr. Nobuhiro
Noro, Glaxo SmithKlein KK, Tokyo, Japan
1230-1330 Lunch
1330-1430 Regulatory
Dr.
1430-1445 Tea break
1445-1600 Example:
Animal model used in pre-clinical studies
Dr. Shigeyuki Kano,
1600-1700 Example:
Leishmaniasis vaccine discovery and clinical trials
Prof. Dr.Ivan Velez, Antioquia
University, Colombia
Clinical Development
24 October, 2007 Wednesday
Overview
0900-1030 Assessment of pre-clinical information
Dr. Howard Engers, AHARI, Ethiopia
1030-1100 Tea Break
1100-1200 Clinical
development plan
Dr. Howard Engers, AHARI,
Ethiopia
1200-1300 Lunch
1300-1430 Application of immunogenicity for
vaccine development
Dr. Shigeharu Ueda, The
Research Foundation for Microbial Diseases
of
1430-1500 Tea break
1500-1600 Dose selection and regimen
Dr. Shigeharu Ueda, The
Research Foundation for Microbial Diseases
of
1600-1730
Participants's report on Vaccine R&D